Market
Amycretin enters Phase 3 trials by mid-2026?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Novo Nordisk press releases and clinical trial registries
Story
Novo Nordisk Shares Surge Over 12% After Amycretin Shows Up to 22% Weight Loss in Early Trial
Jan 24, 2025, 12:00 PM
Novo Nordisk announced positive results from an early-stage Phase 1b/2a trial of its new obesity drug, amycretin. The trial involved 125 participants with overweight or obesity, who achieved up to 22% weight loss over 36 weeks when treated with amycretin. The drug is a novel GLP-1 and amylin receptor agonist designed for once-weekly subcutaneous injection. Following the announcement, Novo Nordisk shares surged more than 12%, their largest increase in a month.
View original story
Similar markets
Successful with significant results • 25%
Successful with moderate results • 25%
Unsuccessful • 25%
Trial not initiated • 25%
Worsening condition • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
No improvement • 25%
Significant improvement • 25%
Moderate improvement • 25%
